QP releaseQualified Person release

Qualified Person (QP) release is the statutory act of certifying a batch of medicinal product for sale or supply in the European Union, European Economic Area, and the United Kingdom. It is personal, traceable, and non‑delegable. A QP’s signature confirms the batch was manufactured and checked in accordance with the Marketing Authorisation, Good Manufacturing Practice (GMP), and applicable law.

Directive 2001/83/EC establishes that no batch may be released until a QP has certified compliance. EudraLex Volume 4, Annex 16 details what constitutes adequate evidence, how the QP should evaluate deviations, and the recordkeeping required. Authorities expect that the QP’s decision is independent, based on documented facts, and supported by a complete and contemporaneous data trail.

QP release is not a clerical tick‑box exercise. It integrates GMP controls from raw materials through finished product testing, packaging, and distribution handover. The QP assures that each batch aligns with the Marketing Authorisation, that critical supplier controls are in place, that required quality system investigations are closed and effective, and that the organization’s manufacturing and control instructions were followed.

While quality units around the world perform batch disposition, the EU and UK system is distinctive in assigning statutory liability to an individual QP named on the manufacturer’s or importer’s authorization. This personal accountability is reflected in inspection expectations, enforcement approaches, and the evidentiary threshold the QP must meet to certify a batch.

The core legal basis is Article 51 of Directive 2001/83/EC for human medicines and the analogous provisions for veterinary products, implemented via national law and interpreted through EudraLex Volume 4 (GMP) and competent authority guidance. Annex 16 is the interpretive standard for QP certification, including definitions of certification versus release to market, evidentiary expectations, and the QP’s responsibility to maintain a certification register.

Scope covers all batches of finished medicinal products intended for the EU, EEA, or UK market, whether manufactured domestically or imported from third countries. QP certification also applies to investigational medicinal products under the applicable clinical trial framework and GMP expectations. In practice, multinational supply chains often require coordination between a manufacturing site QP and an importer QP.

Importation raises specific obligations. The importer must hold an authorization, ensure testing in the Union where required, and demonstrate equivalent GMP. The QP certifying an imported batch must have access to the original manufacturing and testing records, vendor oversight evidence, and transportation controls from the third‑country site to the receiving EU or UK facility.

Repackaging, relabeling, or serialisation activities performed after initial manufacture may trigger the need for additional QP oversight depending on the Marketing Authorisation and the nature of the operations. Annex 16 requires the QP to consider the totality of manufacture and control, including any post‑manufacture manipulations, before certifying a batch for supply.

Where product is imported, Annex 21 provides detailed expectations for importation processes and the relationship between the importer’s authorization and QP responsibilities. The certifying QP should ensure import controls, testing strategies, and third‑country oversight align with the Marketing Authorisation and current GMP.

In all cases, the QP must be qualified, named, and authorized at the site responsible for certification, and must operate within a quality system that ensures timely access to complete, reliable batch evidence.

Further reading on import responsibilities is consolidated in Annex 21 (Importation).

QP certification follows a structured flow: assemble the complete batch evidence, review against the Marketing Authorisation and GMP, resolve discrepancies through formal investigations, and document a clear certification decision tied to a single, attributable signature. The QP should be independent of routine production scheduling pressures, with authority to delay certification until all prerequisites are satisfied.

Complete evidence typically includes the master and executed manufacturing records, analytical release results and trending, stability commitments where applicable, confirmation of component and API control strategies, change control impact assessments, supplier qualification status, and shipping or storage verification up to the point of transfer to GDP control. For imported product, the file must also include import testing records where required and assurance of equivalent GMP at the third‑country manufacturer.

Organizations translate these expectations into standard operating procedures, dossier templates, and checklists. The QP’s certification register must unambiguously map to each batch and to the supporting file. Electronic certification is acceptable when controls ensure data integrity, attribution, and preservation of the “meaning” of a signature. Many teams implement a dedicated electronic release record to separate certification evidence from broader batch documentation while preserving full traceability.

Annex 16 requires that the QP base certification on a defined, comprehensive set of records. Evidence must be contemporaneous, attributable, original or certified true copies, and complete for the full scope of manufacture and control. The Marketing Authorisation, associated variations, and commitments set the acceptance criteria; GMP sets the evidentiary quality bar.

A practical approach is to maintain a standard dossier template that the quality unit populates as each element of manufacture and testing completes. The QP reviews the dossier only after preconditions are met, rather than prospectively certifying while information is still outstanding. Where data integrity risks are identified, the QP should require remediation or enhanced verification before certifying.

Supplier oversight is integral. For active substances and critical excipients, the QP expects to see confirmation that the sourcing and qualification strategy is current and effective, that audit observations are closed, and that change notifications have been assessed for regulatory impact. Transportation verification up to the GDP handover point should also be included.

• Approved master and executed manufacturing records with traceable version control and reconciliation
• Complete analytical package, including method versions, results, OOS/OOT investigations, and final disposition
• Environmental and utility monitoring relevant to the batch and its classification (e.g., aseptic manufacture)
• Supplier qualification status for API and critical materials, with recent audit or assessment evidence
• Change control and deviation files, with impact assessments and effectiveness checks closed
• Importation testing and authorizations where applicable, with chain of custody to receipt
• Stability plan enrollment and, where required, available data supporting release

Annex 16 recognizes that batches may encounter deviations. The QP may certify a batch despite certain deviations only where a documented, science‑based risk assessment demonstrates no negative impact on quality, safety, or efficacy; where root cause and corrective actions are understood; and where the Marketing Authorisation remains satisfied. Such decisions should be exceptional, justified, and transparently recorded in the certification register.

Out‑of‑specification or out‑of‑trend signals require full investigation to completion, with appropriate retesting or resampling only under a scientifically sound, pre‑established protocol. Data integrity expectations mean that inconclusive or procedurally flawed investigations cannot support certification. The QP should use independent challenge and may require external expertise where needed.

Organizations sometimes refer to interim statuses such as “conditional release” within their planning tools. These internal statuses must never permit sale or supply prior to QP certification. If a time‑critical supply scenario exists, a formal risk‑managed process, clear labeling controls, and documented segregation are essential to prevent distribution before the QP signs.

When a batch genuinely cannot meet the Marketing Authorisation or GMP, the appropriate actions are rework within validated and authorized parameters, rejection, or, where legally available, recall for any product that may already have reached the market through error.

In the United States, there is no statutory QP. Batch disposition is performed by the manufacturer’s quality unit under 21 CFR Part 211, including requirements for finished product acceptance at 21 CFR 211.165 and quality unit responsibilities at 21 CFR 211.22. The legal accountability rests with the firm, not with a named individual analogous to the EU or UK QP.

Other mature systems have functional analogues. The UK retained the QP framework post‑Brexit with MHRA guidance. Switzerland, Australia, and Canada apply release‑for‑supply controls through their manufacturing and import authorization regimes, often requiring a responsible person to attest to compliance and, for imported product, to ensure testing and oversight consistent with local law.

PIC/S promotes harmonization of GMP interpretations, including alignment with EU Annex 16 principles. Nevertheless, companies must map site‑specific procedures to the jurisdiction of supply. Where a batch moves across regions, firms often operate a dual‑assurance model: local QA disposition to meet non‑EU rules and separate QP certification for EU or UK supply. Clear segregation of documentation and unambiguous release status labels are essential to avoid premature distribution.

For US‑bound product, release decisions follow 21 CFR 211 and FDA expectations. For EU or UK markets, QP certification is mandatory regardless of similar internal quality approvals. Mixed‑market batches should not be shipped until each jurisdiction’s legal release step is demonstrably complete.

Annex 16 is compatible with modern control strategies, including Real‑Time Release Testing (RTRT) supported by process analytical technology and enhanced process understanding. ICH Q8, Q9, and Q10 provide the scientific and quality system underpinnings. When RTRT replaces or augments traditional end‑product tests, the QP must still verify that the validated control strategy is operating as intended and that the Marketing Authorisation allows the approach.

Digital certification reduces latency and errors by orchestrating structured data into a coherent, reviewable dossier. Effective systems link master data, executed records, deviations, change control, supplier status, and analytical results. They preserve the audit trail and enable timely trending so the QP can form an independent, evidence‑based decision without paper collation delays.

Electronic signatures are acceptable when the system ensures identity verification, signature meaning, and integrity of signed records. Controls should align with EU GMP Annex 11 for computerized systems, and where systems also support US operations, they should be capable of meeting 21 CFR Part 11 expectations for electronic records and signatures. Signature ceremonies and metadata must make the intent of the QP’s certification unmistakable.

RTRT does not eliminate the need for robust investigations. Signals uncovered by continuous monitoring or multivariate analytics demand the same rigor as conventional OOS events. Digital dashboards can help the QP see the whole picture, but the legal decision still hinges on data quality, validation status, and conformance to the Marketing Authorisation.

Inspectors consistently report that delays, omissions, and unclear accountability undermine certification. Weaknesses often trace back to fragmented evidence, incomplete investigations, or supplier oversight that does not keep up with lifecycle changes. The QP’s decision must explicitly account for all critical inputs, and the underlying facts must be organized for efficient, independent review.

Data integrity lapses remain a high‑risk area. Uncontrolled spreadsheets, missing audit trails, and retrospective data entries can make the file unreliable. Where systems blend electronic and paper records, transitions must be clearly controlled, and scanned copies must be certified true with preserved context. Certification registers should be complete, legible, and readily retrievable.

For imported product, reliance on third‑country certificates of analysis without adequate verification, limited access to original manufacturing records, or a superficial assessment of transport conditions can lead to findings. The QP should not certify without full visibility commensurate with risk, including the ability to challenge supplier conclusions.

• Certifying before closing deviations or without effectiveness checks for CAPA
• Inadequate linkage between Marketing Authorisation requirements and executed instructions
• Missing or unclear mapping between certification register entries and batch identifiers
• Insufficient supplier oversight evidence, particularly for API and critical materials
• Weak data integrity controls for hybrid paper–electronic dossiers
• Inadequate verification of import testing strategy or GMP equivalence
• Ambiguous internal statuses that risk distribution before certification

QP certification marks the legal handover point from GMP manufacture and control to Good Distribution Practice (GDP). The QP should confirm that the product leaving the manufacturing authorization site is placed only into a distribution system that meets GDP requirements, with transportation conditions aligned to the product’s label and validated parameters.

Serialization and anti‑tampering features introduced under the EU falsified medicines framework add steps that must be reflected in the dossier. The QP should verify that packaging and safety features match the Marketing Authorisation, that unique identifiers are generated and commissioned correctly where applicable, and that any rework or relabeling has been assessed for impact on verification systems.

For imports, Annex 21 clarifies expectations for oversight of third‑country manufacture, transportation into the Union, and testing strategies. The importer’s quality system must ensure that documents and data reach the certifying QP in time and in full, enabling a decision that is evidence‑based rather than schedule‑driven.

Misalignments often occur when GDP and GMP teams operate on different versions of route qualification, label instructions, or excursion handling. The QP’s review should include a final verification that distribution controls reflect the current product profile, and that systems respond consistently to exceptions.

For background on the distribution and verification environment that follows certification, see EU GDP and the anti‑falsification framework summarized under the Falsified Medicines Directive.

QP certification time is won or lost in how evidence is assembled. V5 Ultimate builds a structured, role‑based dossier as the batch progresses, automatically linking executed records, analytical results, deviations, change controls, supplier status, and shipping data. The result is a single, navigable certification file that the QP can review without hunting through disconnected systems.

Our disposition workflow enforces prerequisites, blocks premature status changes, and surfaces unresolved investigations. Dashboards provide real‑time trending of critical attributes and summarized risk flags, supporting an independent, defensible decision. For imports, the dossier can incorporate third‑country batch data and import testing outcomes, maintaining chain‑of‑custody context up to GDP handover.

Electronic certification is secured with validated signature ceremonies and audit trails. Where firms operate globally, the same controls support EU Annex 11 and 21 CFR Part 11 expectations. Templates map evidence to the Marketing Authorisation, reducing narrative gaps and making inspections smoother. When RTRT is implemented, V5 associates process signals and models with batch identity so the QP can verify control strategy performance alongside traditional results.